Repurposing of Meropenem and Nadifloxacin for Treatment of Burn Patients?
| Autor: | James Spencer, Christie Costa, Janice D. Thomas, Karla Bullon, Joseph G. Moloughney, Jeffrey H. Toney |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Pharmacology
Pseudomonas aeruginosa business.industry medicine.drug_class Antibiotics medicine.disease_cause Meropenem Microbiology Multiple drug resistance chemistry.chemical_compound Antibiotic resistance chemistry Drug development medicine General Materials Science Nadifloxacin business Repurposing medicine.drug |
| Zdroj: | Nature Precedings |
| Popis: | The escalating number of multidrug resistant pathogens has demanded the swift development of new and potent antibiotics (ref. 2). Metallo-[beta]-lactamases (MBLs) continue to evolve, rendering the latest generation of carbapenem antibiotics useless (ref. 8). SPM-1, a recently discovered MBL, was isolated from a juvenile leukemia patient residing in a hospital in San Palo, Brazil just prior to the patient succumbing to septicemia brought on by Pseudomonas aeruginosa expressing SPM-1 (ref. 8). Screening of the Johns Hopkins Compound library of 1,514 FDA or FAD approved drugs (ref. 1) identified a novel SPM-1 inhibitor that is synergistically compatible with meropenem. Using clinically achievable concentrations, meropenem coupled with nadifloxacin inhibits Pseudomonas aeruginosa expressing SPM-1. This shotgun approach to new drug discovery provided a prompt solution to the grave problem of antibiotic resistant pathogens that are thriving in hospitals today. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|